Panuveitis
Definition
Inflammation involving all segments of the uveal tract simultaneously, associated with conditions including sarcoidosis, Vogt-Koyanagi-Harada disease, Behçet disease, and sympathetic ophthalmia.
Clinical Snapshot
Panuveitis is defined by simultaneous inflammation of the anterior segment, vitreous, and posterior segment. It represents the most severe anatomical form of uveitis and is almost always associated with significant systemic disease. The major causes include sarcoidosis, Vogt-Koyanagi-Harada (VKH) disease, Behçet disease, sympathetic ophthalmia, and syphilis. Systemic evaluation is mandatory — the ocular findings are frequently the presenting manifestation of serious systemic disease. Management typically requires systemic immunosuppression.
Epidemiology
Panuveitis accounts for approximately 7–15% of uveitis cases. The etiology varies significantly by geographic region and patient demographics. VKH disease is more common in Asian, Hispanic, and Native American populations. Behçet disease is more common in patients from the Middle East, Central Asia, and East Asia (the "Silk Road" distribution).
Pathophysiology
Panuveitis results from severe, diffuse uveal inflammation that crosses anatomical compartments. In VKH disease, T-cell–mediated autoimmunity against melanocyte antigens causes choroidal inflammation, exudative retinal detachment, and anterior segment involvement. In Behçet disease, neutrophil-mediated vasculitis affects retinal vessels and the uveal tract. In sarcoidosis, non-caseating granulomas infiltrate the uveal tract at all levels.
Risk Factors
- Sarcoidosis
- VKH disease (Asian, Hispanic, Native American ancestry)
- Behçet disease (HLA-B51; Middle Eastern, Central Asian, East Asian ancestry)
- Sympathetic ophthalmia (prior penetrating ocular trauma or surgery)
- Syphilis (must be excluded in all panuveitis)
- Tuberculosis (endemic regions)
Clinical Presentation
Simultaneous anterior chamber cells and flare, vitritis, and posterior segment involvement (chorioretinitis, retinal vasculitis, disc edema, exudative retinal detachment). VKH: bilateral exudative retinal detachments, disc hyperemia, choroidal thickening, and systemic features (headache, tinnitus, dysacusis, vitiligo, poliosis). Behçet: occlusive retinal vasculitis, hypopyon uveitis, and oral/genital ulcers. Sarcoidosis: multifocal choroidal granulomas, periphlebitis ("candle wax drippings"), and disc granulomas.
Diagnostic Pearls
- Syphilis serology (RPR/FTA-ABS) is mandatory in all panuveitis — syphilis is the "great imitator" and is treatable.
- VKH disease has a prodromal phase (meningismus, tinnitus, dysacusis) — a careful history may reveal it before the ocular phase.
- Behçet disease diagnosis requires recurrent oral ulcers plus two of: genital ulcers, skin lesions, ocular disease, or positive pathergy test.
- ICGA is the most sensitive imaging modality for choroidal involvement in VKH and sarcoidosis.
Differential Diagnosis
- Ocular lymphoma (masquerade — particularly in older patients)
- Endophthalmitis (acute onset, more pain)
- Infectious panuveitis (CMV, syphilis, tuberculosis)
Evidence-Based Management
Systemic corticosteroids are the cornerstone of initial management for non-infectious panuveitis — high-dose prednisone (1–1.5 mg/kg/day) for acute disease. VKH: high-dose systemic corticosteroids with very slow taper over 6–12 months; early steroid-sparing immunosuppression reduces recurrence. Behçet: systemic corticosteroids + colchicine; biologics (infliximab, adalimumab, interferon-α) for refractory disease. Sarcoidosis: systemic corticosteroids; methotrexate or mycophenolate for steroid-sparing. Syphilitic panuveitis: IV penicillin G (neurosyphilis protocol).
Monitoring & Follow-Up
Frequent follow-up during active disease — weekly during acute phase. OCT, fluorescein angiography, and ICGA to monitor treatment response. Systemic co-management with rheumatology, internal medicine, or neurology as appropriate.
Clinical Pearls
- Panuveitis demands a systemic diagnosis — do not manage it as isolated ocular disease.
- VKH disease requires a prolonged corticosteroid taper (6–12 months) — premature taper causes the "sunset glow fundus" chronic phase with worse outcomes.
- Behçet uveitis is occlusive and can cause rapid, irreversible vision loss — early aggressive treatment with biologics is often warranted.
- Syphilis must be excluded in every panuveitis patient — it is treatable and can mimic any uveitis entity.
Related Therapeutics — Clinician's Companion
- Oral Therapeutics — Oral Prednisone, Methotrexate (Clinician's Companion)
- Anti-inflammatory Rescue — Pred Forte®, Durezol® (Clinician's Companion)
Key References
- 1.Read RW, et al. Diagnostic criteria for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001.
- 2.Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet. 1990.
This entry is an educational reference designed to support clinical reasoning and awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current guidelines and applicable clinical resources when making patient care decisions.